Business Context and Reporting Period
Company: Novo Nordisk A/S
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2015
Accounting Standards: International Financial Reporting Standards (IFRS)
Currency: Danish Kroner (DKK)
Novo Nordisk is a global healthcare company and a world leader in diabetes care, with additional leading positions in haemophilia care, growth hormone therapy, and hormone replacement therapy. The company operates in two segments: diabetes and obesity care, and biopharmaceuticals. In 2015, the company divested 74.5% of its IT service provider, NNIT A/S, recognizing a non-recurring net gain of DKK 2,376 million.
Key Financial Metrics
| Metric (DKK Millions) | 2015 | 2014 |
|---|---|---|
| Net Sales | 107,927 | 88,806 |
| Operating Profit | 49,444 | 34,492 |
| Net Profit | 34,860 | 26,481 |
| Earnings Per Share (DKK) | 13.56 | 10.10 |
| Free Cash Flow | 34,222 | 27,396 |
| Total Assets | 91,799 | 77,062 |
| Net Assets (Equity) | 46,969 | 40,294 |
| Long-term Debt | None | None |
Liquidity: Financial resources at year-end totaled DKK 27,601 million, comprising cash, cash equivalents, bonds, and undrawn committed credit facilities. The company reported no long-term loans outstanding as of December 31, 2015.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased by 21.5% to DKK 107,927 million, driven by volume growth, new product launches (Tresiba, Ryzodeg, Saxenda), and favorable exchange rates.
- Profitability: Operating profit rose 43.3% to DKK 49,444 million. Net profit increased 31.6% to DKK 34,860 million.
- One-time Gain: The divestment of NNIT A/S contributed a non-recurring net gain of DKK 2,376 million to the 2015 income statement.
- Capital Expenditure: Net capital expenditure increased to DKK 5.2 billion in 2015 from DKK 4.0 billion in 2014, focused on insulin filling capacity and biopharmaceutical manufacturing expansion.
- Share Repurchases: The company completed a DKK 17.5 billion share repurchase program in January 2016, having repurchased 48.2 million shares during 2015.
Guidance, Outlook, and Risks
Outlook: Management expects to invest approximately DKK 7.0 billion in fixed assets in 2016. Growth is expected to be driven by the roll-out of new products (Tresiba, Ryzodeg, Xultophy, Saxenda) and the increasing global prevalence of diabetes and obesity. A decline in sales of Vagifem is expected starting in 2016 due to loss of exclusivity in the U.S.
Risks and Contingencies:
- Patent Expirations: Key products like NovoLog/NovoRapid and NovoSeven face patent expirations, though formulation patents and regulatory complexities for biosimilars are expected to mitigate near-term impacts.
- Regulatory and Pricing Pressure: Global payers continue to exert pressure on product prices. The company ceased distribution of Tresiba in Germany in January 2016 following negative price negotiations.
- Geopolitical: The company conducts business in Iran, Crimea, Syria, Sudan, and Cuba. Gross revenue from these regions was not in excess of DKK 80 million each, with Iran-related gross revenue not exceeding DKK 750 million.
- Foreign Exchange: Significant exposure to USD, CNY, JPY, GBP, and CAD fluctuations, though EUR risk is low due to the Danish fixed-rate policy.
Investor Verification Checklist
- Dividend Proposal: Verify the proposed dividend of DKK 6.40 per share (46.6% payout ratio) at the Annual General Meeting.
- Non-IFRS Measures: Review the reconciliation of "Free Cash Flow" (DKK 34,222 million) and "Cash to Earnings" (98.2%) against IFRS operating cash flow.
- Share Repurchase Program: Confirm the execution of the new DKK 14.0 billion share repurchase program announced in February 2016.
- Patent Portfolio: Assess the impact of formulation patents expiring in 2017 for NovoLog/NovoRapid and Norditropin on future revenue streams.
- Capital Allocation: Monitor the DKK 12 billion investment planned for the new diabetes API facility in Clayton, North Carolina, expected to be operational in 2020.